Public disclosures

Patel Sanjiv

Company insiders · President and CEO · Director · Relay Therapeutics, Inc.

Advertisement
FollowLatest SEC filingSEC filer historyProfile details as reported on 2026-11-20.Following & alerts
Reported transaction lines
1
Buy lines
0
Sell lines
1

Filing activity by month

Original filing lines in up to 12 months with activity.

  • 2026-111

Frequently disclosed stocks

Disclosure history

More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSource
Patel Sanjiv

President and CEO · Director · Relay Therapeutics, Inc.

RLAY

Relay Therapeutics, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 423099 · SEC code covers open-market or private transactions · The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. · This transaction was executed in multiple trades at prices ranging from $15.89 to $16.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

2026-11-192026-11-20

≈ $777,498.26

48,202 shares/units

SEC 4

Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.

Advertisement